Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Insights into EPIM-001 for the treatment of hematological malignancies

Yan Chen, MD, PhD, Elpis Biopharmaceuticals, Boston, MA, discusses the development of EPIM-001, a bi-functional IL2Rβ agonist and anti-PDL1 biologic. Explicitly, EPIM-001 is a tumor-targeted IL2 agonist with reduced IL2Rα binding and enhanced IL2Rβ binding. EPIM-001 was engineered using the mSCAFold™ engineering platform which improves pharmacologic properties. Further, the relatively long half-life of EPIM-001 means that less frequent doses are required compared to the soluble IL2. Dr Chen explains that EPIM-001 could treat the PDL1-low patient population and those who are relapsed or resistant to current immune checkpoint treatments. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.